Risk assessment and molecular mechanism study of drug-drug interactions between rivaroxaban and tyrosine kinase inhibitors mediated by CYP2J2/3A4 and BCRP/P-gp
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.